Martin Bergstrand, Ph.D.

Principal Director, MIDD Scientific Lead

Portrait-of-Martin-Bergstrand_Pharmetheus

Bio

  • Co-founded Pharmetheus in 2012, actively working in client projects, serving as MIDD Scientific Lead
  • Expertise includes trial design, pharmacometrics (especially complex pharmacokinetics, mechanism based PKPD and Markov models), and model informed drug development in therapeutic areas such as infectious, metabolic, and cardiovascular diseases
  • Previously worked as part-time Researcher at Uppsala University, Sweden, where he performed pharmacometric research primarily by supervision of Ph.D. students, as Visiting Scientist at Mahidol-Oxford Tropical Medicine Research Unit, Thailand, and Clinical Pharmacology Scientist at AstraZeneca R&D Mölndal, Sweden
  • M.Sc. in Biomedicine (2003) from University of Kalmar, Sweden, and Ph.D. in Pharmaceutical Biosciences (2011) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

The visual predictive check and real-world dataReference-corrected VPCs: addressing model evaluation challenges with real-world data and adaptive designsModel-informed pediatric drug development for clevidipineVisual predictive checks for real-world data using propensity-score-matchingModel-integrated evidence: A vision to expandthe role of modeling in drug development andregulatory decision-makingApparent time dependence and rethinking random effect under single time-to-event modelsPopulation pharmacokinetics and exposure-response analyses of navepegritide in children with achondroplasiaBenchmarking a mechanistic immunogenicity framework: aligning sequence-based epitope predictions with clinical observationsVisual predictive checks for real-world data using propensity-score-matchingThe use of full random effect models (FREM) in model informed precision dosing (MIPD) for a priori dose predictionsExposure-response analysis for time-to-event data in the presence of adaptive dosing: efficient approaches and pitfalls (Poster)